Roche receives FDA De Novo authorization for cobas® pro i 601 platform with Ionify® Gabapentin assay, advancing automated mass spectrometry for routine clinical laboratories
Article excerpt
INDIANAPOLIS, Nov. 16, 2026 /PRNewswire/ -- Roche (SIX: RO, ROP; OTCQX: RHHBY ) announced today that the U.S. Food and Drug Administration (FDA) has granted De Novo authorization for the cobas® pro i 601 platform with the Ionify® Gabapentin assay, components of its cobas® Mass Spec solution. Designed to bring advanced mass spectrometry testing into routine clinical laboratories, the solution combines the analytical capabilities of mass spectrometry with an automated, standardized workflow – expanding Roche's diagnostic menu into therapeutic drug monitoring. Mass spectrometry is widely used for clinical applications requiring highly sensitive and specific measurement, but traditional methods often involve specialized personnel and complex manual workflows. Roche is pioneering the transition of mass spectrometry from specialized reference facilities to the core laboratory, redefining complex testing into an accessible, standardized solution for routine clinical practice. Authorized through the De Novo pathway, the Ionify® Gabapentin assay adds a therapeutic drug monitoring application to a U.S. menu that includes 25-Hydroxy Vitamin D total and steroid hormone testing assays, such as estradiol and 17-Hydroxyprogesterone. Roche continues to develop additional clinical mass spectrometry assays to broaden the menu over time. Demonstrating an innovative, collaborative approach...
Keep reading with a free account
The rest of this article, and every signal for Roche, is in your free account.
Extracted from this sentence
The authorized PCCP includes the expansion of up to 22 Ionify® assays on the cobas® pro i 601 platform as PCCP requirements are met.
